ArticleOncology letters2017
Downregulation of miR-30a is associated with proliferation and invasion via targeting MEF2D in cervical cancer.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Advances in exosome biomarkers for cervical cancer.Cancer medicine · 2022Review
- Article
- Small Non-Coding-RNA in Gynecological Malignancies.Cancers · 2021Review
- Role of microRNAs in epidermal growth factor receptor signaling pathway in cervical cancer.Molecular biology reports · 2020Review
- Knockdown of LncRNA DLEU2 Inhibits Cervical Cancer Progression via Targeting miR-128-3p.OncoTargets and therapy · 2020Article
- Identification and performance evaluation of housekeeping genes for microRNA expression normalization by reverse transcription-quantitative PCR using liquid-based cervical cytology samples.Oncology letters · 2019Article
- The role of miRNAs in the invasion and metastasis of cervical cancer.Bioscience reports · 2019Review
- MiR-155-5p accelerates the metastasis of cervical cancer cell via targeting TP53INP1.OncoTargets and therapy · 2019Article
- MicroRNA-217 acts as a tumor suppressor and correlates with the chemoresistance of cervical carcinoma to cisplatin.OncoTargets and therapy · 2019Article
- Long noncoding RNA DLEU1 aggravates glioma progression via the miR-421/MEF2D axis.OncoTargets and therapy · 2019Article
- MicroRNA-183-5p Inhibits Aggressiveness of Cervical Cancer Cells by Targeting Integrin Subunit Beta 1 (ITGB1).Medical science monitor : international medical journal of experimental and clinical research · 2018Article
Corrections and comments
- Retraction · 2023-11-27Author Unresponsive · Euphemisms for Plagiarism · Investigation by Journal/Publisher · Investigation by Third Party · Plagiarism of Data · Plagiarism of Image · · See also: https://pubpeer.com/publications/050C8AA3813CCBDFFE45C3E27CAC58
- Retracted
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating studies have revealed that microRNAs serve crucial roles in cancer development and progression. MicroRNA-30a (miR-30a) has been implicated in various cancer types. However, the role of miR-30a in cervical cancer remains unclear. In the current study, a reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay revealed that miR-30a was significantly downregulated in cervical cancer tissues compared with adjacent normal tissues, and in the cervical cancer cell lines HeLa, SiHa and Ca-Ski compared with GH329 normal cervical epithelial cells. A functional assay using miR-30a mimic demonstrated that miR-30a could inhibit the growth and invasion of cervical cancer cells. Additionally, bioinformatics-based prediction and luciferase reporter assays indicated that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.